David Matheson

David Matheson

University of Wolverhampton - Wolverhampton / United Kingdom
Education / Education (Other, All)
AD Scientific Index ID: 1481660
person_outline David Matheson's MOST POPULAR ARTICLES
1-) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...The Lancet 387 (10024), 1163-1177, 201617712016
2-) Abiraterone for prostate cancer not previously treated with hormone therapyND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...New England Journal of Medicine 377 (4), 338-351, 201714142017
3-) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialCC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...The Lancet 392 (10162), 2353-2366, 20187872018
4-) Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialNW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...Annals of Oncology 30 (12), 1992-2003, 20194142019
5-) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...Annals of Oncology 29 (5), 1235-1248, 20182902018